HomeCompareTSSNF vs PFE

TSSNF vs PFE: Dividend Comparison 2026

TSSNF yields 40000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TSSNF wins by $5.18024517379999e+22M in total portfolio value
10 years
TSSNF
TSSNF
● Live price
40000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.18024517379999e+22M
Annual income
$51,548,940,318,215,365,000,000,000,000.00
Full TSSNF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — TSSNF vs PFE

📍 TSSNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTSSNFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TSSNF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TSSNF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TSSNF
Annual income on $10K today (after 15% tax)
$3,400,000.00/yr
After 10yr DRIP, annual income (after tax)
$43,816,599,270,483,060,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, TSSNF beats the other by $43,816,599,270,483,060,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TSSNF + PFE for your $10,000?

TSSNF: 50%PFE: 50%
100% PFE50/50100% TSSNF
Portfolio after 10yr
$2.590122586899995e+22M
Annual income
$25,774,470,159,107,683,000,000,000,000.00/yr
Blended yield
99.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

TSSNF
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TSSNF buys
0
PFE buys
0
No recent congressional trades found for TSSNF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTSSNFPFE
Forward yield40000.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$5.18024517379999e+22M$49.6K
Annual income after 10y$51,548,940,318,215,365,000,000,000,000.00$26,258.71
Total dividends collected$5.178579568047658e+22M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TSSNF vs PFE ($10,000, DRIP)

YearTSSNF PortfolioTSSNF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$4,010,700$4,000,000.00$9,153$693.39+$4.00MTSSNF
2$1,503,618,552$1,499,327,102.80$8,593$849.25+$1503.61MTSSNF
3$526,936,342,129$525,327,470,278.19$8,336$1,066.78+$526936.33MTSSNF
4$172,618,628,820,566$172,054,806,934,488.28$8,437$1,384.80+$172618628.81MTSSNF
5$52,860,672,107,805,460$52,675,970,174,967,450.00$9,013$1,875.40+$52860672107.80MTSSNF
6$15,132,132,379,588,594,000$15,075,571,460,433,242,000.00$10,306$2,680.72+$15132132379588.58MTSSNF
7$4,049,462,878,006,525,600,000$4,033,271,496,360,366,000,000.00$12,820$4,101.38+$4049462878006525.50MTSSNF
8$1,013,053,710,099,385,500,000,000$1,008,720,784,819,918,400,000,000.00$17,673$6,826.70+$1013053710099385472.00MTSSNF
9$236,926,560,546,299,530,000,000,000$235,842,593,076,493,200,000,000,000.00$27,543$12,591.86+$236926560546299510784.00MTSSNF
10$51,802,451,737,999,890,000,000,000,000$51,548,940,318,215,365,000,000,000,000.00$49,560$26,258.71+$5.18024517379999e+22MTSSNF

TSSNF vs PFE: Complete Analysis 2026

TSSNFStock

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, and GBM-V & Cardiac divisions. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductive to stimulate and regenerate native bone growth. In addition, the company provides DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, Decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. Further, it offers OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company provides DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; CardioPure products; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks for ophthalmology and wound covering; and sports medicine products. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.

Full TSSNF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this TSSNF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TSSNF vs SCHDTSSNF vs JEPITSSNF vs OTSSNF vs KOTSSNF vs MAINTSSNF vs JNJTSSNF vs MRKTSSNF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.